<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>ABSTRACT: BACKGROUND: Microvascular and macrovascular complications in <z:mp ids='MP_0002055'>diabetes</z:mp> stem from <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> and are thought to have overlapping pathophysiology </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to investigate the incidence rate of hospitalized <z:hpo ids='HP_0001658'>myocardial infarctions</z:hpo> (MI) and <z:hpo ids='HP_0001297'>cerebrovascular accidents</z:hpo> (<z:chebi fb="4" ids="46274">CVA</z:chebi>) in patients with diabetic macular <z:hpo ids='HP_0000969'>edema</z:hpo> (<z:chebi fb="121" ids="42263">DME</z:chebi>) compared with diabetic patients without <z:chebi fb="46" ids="15035">retinal</z:chebi> diseases </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: This was a retrospective cohort study of a commercially insured population in an administrative claims database </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="121" ids="42263">DME</z:chebi> subjects (n = 3519) and <z:mp ids='MP_0002055'>diabetes</z:mp> controls without <z:chebi fb="46" ids="15035">retinal</z:chebi> disease (n = 10557) were matched by age and gender </plain></SENT>
<SENT sid="4" pm="."><plain>Healthcare claims were analyzed for the study period from 1 January 2002 to 31 December 2005 </plain></SENT>
<SENT sid="5" pm="."><plain>Incidence and adjusted rate ratios of hospitalized MI and <z:chebi fb="4" ids="46274">CVA</z:chebi> events were then calculated </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The adjusted rate ratio for MI was 2.50 (95% CI: 1.83-3.41, p &lt; 0.001) for <z:chebi fb="121" ids="42263">DME</z:chebi> versus <z:mp ids='MP_0002055'>diabetes</z:mp> controls </plain></SENT>
<SENT sid="7" pm="."><plain>Predictors of MI events were <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e>, history of <z:hpo ids='HP_0011009'>acute</z:hpo> MI, and prior use of antiplatelet or <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> drugs </plain></SENT>
<SENT sid="8" pm="."><plain>The adjusted rate ratio for <z:chebi fb="4" ids="46274">CVA</z:chebi> was 1.98 (95% CI: 1.39-2.83, p &lt; 0.001) for <z:chebi fb="121" ids="42263">DME</z:chebi> versus <z:mp ids='MP_0002055'>diabetes</z:mp> controls </plain></SENT>
<SENT sid="9" pm="."><plain>Predictors of <z:chebi fb="4" ids="46274">CVA</z:chebi> events were <z:hpo ids='HP_0011675'>cardiac arrhythmia</z:hpo>, Charlson comorbidity scores, history of <z:chebi fb="4" ids="46274">CVA</z:chebi>, <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo>, and <z:e sem="disease" ids="C0393949" disease_type="Disease or Syndrome" abbrv="">other cerebrovascular diseases</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: Event rates of MI or <z:chebi fb="4" ids="46274">CVA</z:chebi> were higher in patients with <z:chebi fb="121" ids="42263">DME</z:chebi> than in <z:mp ids='MP_0002055'>diabetes</z:mp> controls </plain></SENT>
<SENT sid="11" pm="."><plain>This study is one of few with sufficient sample size to accurately estimate the relationship between <z:chebi fb="121" ids="42263">DME</z:chebi> and cardiovascular outcomes </plain></SENT>
</text></document>